Aura Biosciences names Jill Hopkins CMO, Mark Plavsic CTO

Aura Biosciences announced the appointments of Jill Hopkins, M.D., as Chief Medical Officer, President of Research & Development, and Mark Plavsic, Ph.D., as Chief Technology Officer. The company also announced that Cadmus Rich, M.D., will step down as Chief Medical Officer and assume a new role with the company as Senior Clinical Advisor. “Jill and Mark’s appointments come at an important time in Aura‘s evolution as a late stage clinical development company,” said Elisabet de los Pinos, Ph.D., Chief Executive Officer of Aura. “We have built our leadership team with experienced industry leaders who have proven track records of success with multiple drug approvals. With bel-sar commencing in a global Phase 3 trial the organization is now positioned for its next phase of growth, with the goal of bringing the first vision-preserving targeted therapy for patients with early-stage choroidal melanoma to market.”